VOYAGER PAD, Revisited with Marc Bonaca, MD, MPH

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

New subgroup analyses from the VOYAGER PAD trial suggest 2.5 mg rivaroxaban plus aspirin provides consistent benefit in reducing risk of possibly fatal events in patients with critical limb ischemia (CLI) and diabetes.

The findings, presented by Marc Bonaca, MD, MPH, of CPC Clinical Research at the American Diabetes Association (ADA) 2021 Scientific Sessions this week, contribute to cardiovascular care on multiple levels.

First, it helps define the scope and scale of burden patients with comorbid diabetes and peripheral artery disease (PAD) face in limb and cardiac events—even when compared to patients with lone PAD.

Next—and most importantly—it establishes opportunity of care for millions of at-risk patients with a proven vascular therapy.

In the fourth episode of Heart Trials, Bonaca joined HCPLive during ADA 2021 to share perspective on the newest VOYAGER PAD analysis.

Along the way, Bonaca touched on the burdens of PAD on patients with diabetes, the continuation of VOYAGER PAD assessment, and the pursuit of patient-impacting clinical outcomes.

Listen to Heart Trials on your favorite podcast platforms, including Spotify and Apple Podcasts.